



Clinical Trial Details (PDF Generation Date :- Fri, 12 Feb 2021 04:51:51 GMT)

<b>CTRI Number</b>	CTRI/2017/03/008246 [Registered on: 29/03/2017] - <b>Trial Registered Prospectively</b>		
<b>Last Modified On</b>	16/02/2018		
<b>Post Graduate Thesis</b>	No		
<b>Type of Trial</b>	Interventional		
<b>Type of Study</b>	Nutraceutical		
<b>Study Design</b>	Randomized, Parallel Group, Multiple Arm Trial		
<b>Public Title of Study</b>	Low Protein Diet Supplementation Study in Non-Diabetic Kidney Disease Patients		
<b>Scientific Title of Study</b>	A Randomized, Open Label, Three Arm, Comparative, Controlled, Single-center Study to Evaluate the Effect of Low Protein Diet Supplementation with Taurine and N-Acetylcysteine (Tab. Nefrosave) and N-Acetylcysteine and Pyridoxamine Dihydrochloride (Tab. Nefrosave Forte) in Preventing Progression of Chronic Renal Failure in Patients with Non-Diabetic Kidney Disease.		
<b>Secondary IDs if Any</b>	<b>Secondary ID</b>	<b>Identifier</b>	
	BVC/CRF-NDKD/2016 Version: 02 Date: 08 September 2016	Protocol Number	
<b>Details of Principal Investigator or overall Trial Coordinator (multi-center study)</b>	<b>Details of Principal Investigator</b>		
	<b>Name</b>	Dr Pratim Sengupta	
	<b>Designation</b>	Consultant Transplant Physician & Nephrologist	
	<b>Affiliation</b>	Belle Vue Clinic	
	<b>Address</b>	9, Dr. U.N. Brahmachari Street, Kolkata Kolkata WEST BENGAL 700017 India	
	<b>Phone</b>	09830099686	
	<b>Fax</b>		
	<b>Email</b>	Pratim.sengupta@gmail.com	
	<b>Details Contact Person (Scientific Query)</b>	<b>Details Contact Person (Scientific Query)</b>	
		<b>Name</b>	Dr Pratim Sengupta
<b>Designation</b>		Consultant Transplant Physician & Nephrologist	
<b>Affiliation</b>		Belle Vue Clinic	
<b>Address</b>		9, Dr. U.N. Brahmachari Street, Kolkata Kolkata WEST BENGAL 700017 India	
<b>Phone</b>		09830099686	
<b>Fax</b>			
<b>Email</b>		Pratim.sengupta@gmail.com	
<b>Details Contact Person (Public Query)</b>	<b>Details Contact Person (Public Query)</b>		
	<b>Name</b>	Subhash Sugathan	
	<b>Designation</b>	Consultant Regulatory Affairs and Quality Assurance	
	<b>Affiliation</b>	QAscent Research Solutions Pvt. Ltd.	
	<b>Address</b>	B 103, STREET NO. 4, JYOTI COLONY, NEAR DURGAPURI CHOWK, SHAHDRA East DELHI 110032 India	



	<b>Phone</b>	09971008625		
	<b>Fax</b>			
	<b>Email</b>	subhash@qascentresearch.com		
<b>Source of Monetary or Material Support</b>	<b>Source of Monetary or Material Support</b>			
	> The Kidney Care Society 29/10 Harey Krishno Seth lane, Kolkata-700050, West Bengal, India			
<b>Primary Sponsor</b>	<b>Primary Sponsor Details</b>			
	<b>Name</b>	Dr Pratim Sengupta		
	<b>Address</b>	Belle Vue Clinic, 9, Dr. U.N. Brahmachari Street, Kolkata-700017 West Bengal, India		
	<b>Type of Sponsor</b>	Other [Investigator Initiated ]		
<b>Details of Secondary Sponsor</b>	<b>Name</b>	<b>Address</b>		
	QASCENT RESEARCH SOLUTIONS PVT LTD	B 103, Street No. 4, Jyoti Colony, Near Durgapuri Chowk, Shahdara, East Delhi 110032,INDIA		
<b>Countries of Recruitment</b>	<b>List of Countries</b>			
	India			
<b>Sites of Study</b>	<b>Name of Principal Investigator</b>	<b>Name of Site</b>	<b>Site Address</b>	<b>Phone/Fax/Email</b>
	Dr Pratim Sengupta	Belle Vue Clinic	Nephrology Department, 9, Dr. U.N. Brahmachari Street Kolkata WEST BENGAL	09830099686 Pratim.sengupta@gmail.com
<b>Details of Ethics Committee</b>	<b>Name of Committee</b>	<b>Approval Status</b>	<b>Date of Approval</b>	<b>Is Independent Ethics Committee?</b>
	Institutional Ethics Committee Belle Vue Clinic	Approved	20/09/2016	No
<b>Regulatory Clearance Status from DCGI</b>	<b>Status</b>		<b>Date</b>	
	Not Applicable		No Date Specified	
<b>Health Condition / Problems Studied</b>	<b>Health Type</b>		<b>Condition</b>	
	Patients		Non-Diabetic Kidney Disease	
<b>Intervention / Comparator Agent</b>	<b>Type</b>	<b>Name</b>	<b>Details</b>	
	Intervention	Low protein diet supplemented with (Taurine (500 mg) and N-Acetylcysteine (150 mg)) tablet	Low protein diet (0.6g of proteins per kilo of body weight per day) supplemented with Nefrosave (Taurine (500 mg) and N-Acetylcysteine (150 mg)) tablet; Route: Oral; Frequency: One tablet twice daily; Duration of Therapy: 6 Months	
	Intervention	Low protein diet supplemented with (N-Acetylcysteine (300 mg) and Pyridoxamine Dihydrochloride (50 mg)) tablet	Low protein diet (0.6g of proteins per kilo of body weight per day) supplemented with Nefrosave Forte (N-Acetylcysteine (300 mg) and Pyridoxamine Dihydrochloride (50 mg)) tablet; Route: Oral; Frequency: One tablet twice daily; Duration of Therapy: 6 Months	
	Comparator Agent	Low protein diet	Low protein diet (0.6g of	



		proteins per kilo of body weight per day); Route: Any Route; Frequency: Per day 0.6 g of Protein per kilo of body weight during three meals a day; Duration of Therapy: 6 Months
<b>Inclusion Criteria</b>	<b>Inclusion Criteria</b>	
<b>Age From</b>	18.00 Year(s)	
<b>Age To</b>	70.00 Year(s)	
<b>Gender</b>	Both	
<b>Details</b>	1)Ability to understand and provide informed consent for participation in the study 2)Males or females ?18 or ?70 years of age 3)Chronic renal failure patients with GFR more than 15 ml/min/1.73m <sup>2</sup> and less than 60ml/min/1.73m <sup>2</sup> receiving standard of care based on investigator's discretion 4)Life expectancy greater than one year 5)Non diabetic patients 6)Well controlled blood pressure (MAP10gm/day 6)Hb16g/dl 7)BMI 30 kg/m <sup>2</sup> 8)Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from Day 1 until the month 6 visit 9)Participation in other product clinical trial within 30 days' prior to this trial 10)Any other systemic disease or any other abnormal laboratory values which as per investigator will interfere with patient's participation in study	
<b>Method of Generating Random Sequence</b>	Random Number Table	
<b>Method of Concealment</b>	Pre-numbered or coded identical Containers	
<b>Blinding/Masking</b>	Open Label	
<b>Primary Outcome</b>	<b>Outcome</b>	<b>Timepoints</b>
	The rate of change of GFR (Slope)	Month 3
<b>Secondary Outcome</b>	<b>Outcome</b>	<b>Timepoints</b>
	Urinary creatinine clearance	Month 3 and Month 6
	Measurement of serum creatinine after 8 hours fast	Month 1, Month 2, Month 3, Month 4, Month 5 and Month 6
	eGFR will be calculated by MDRD formula	Month 1, Month 2, Month 3, Month 4, Month 5 and Month 6
<b>Target Sample Size</b>	<b>Total Sample Size=75</b> <b>Sample Size from India=75</b> <b>Final Enrollment numbers achieved (Total)=Applicable only for Completed/Terminated trials</b> <b>Final Enrollment numbers achieved (India)=Applicable only for Completed/Terminated trials</b>	
<b>Phase of Trial</b>	N/A	
<b>Date of First Enrollment (India)</b>	17/04/2017	
<b>Date of First Enrollment (Global)</b>	No Date Specified	
<b>Estimated Duration of Trial</b>	<b>Years=1</b> <b>Months=5</b>	



<b>Recruitment Status of Trial (Global)</b>	<b>Days=0</b> Not Applicable
<b>Recruitment Status of Trial (India)</b>	Open to Recruitment
<b>Publication Details</b>	None Yet
<b>Brief Summary</b>	<p>The study protocol BVC/CRF-NDKD/2016 is a randomized, open label, three arm, controlled, single-center study to evaluate the effect of low protein diet supplementation with taurine and n-acetylcysteine (tab. Nefrosave) and n-acetylcysteine and pyridoxamine dihydrochloride (tab. Nefrosave Forte) in preventing progression of chronic renal failure in patients with non-diabetic kidney disease.</p> <p>Patients with chronic renal disease, not on dialysis and satisfying the study eligibility criteria will be enrolled in this study. All patients satisfying the study eligibility criteria will be randomly (using random number table) assigned in 1:1:1 ratio, on any one of the three study arms:</p> <p><b><u>Study Arm-1:</u></b></p> <p>Low protein diet (0.6g/kg BW/day)</p> <p><b><u>Study Arm-2:</u></b></p> <p>Low protein diet (0.6g/kg BW/day) supplemented with Nefrosave tablet (500mg Taurine + 150 mg NAC); <b>Dose: 1 tab twice daily</b></p> <p><b><u>Study Arm-3:</u></b></p> <p>Low protein diet supplemented with Nefrosave Forte tablet (300 mg NAC+ 50 mg pyridoxamine dihydrochloride); <b>Dose: 1 tab twice daily</b></p>